Rakovina Advances AI-Assisted Brain-Penetrant ATR Program

Rakovina said its collaboration with Variational AI advanced ATR inhibitor leads to an optimization stage after synthesizing 122 compounds over about two years with approximately $1 million in direct external spend. The program remains preclinical, with candidate selection pending.